BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bodei L, Schöder H, Baum RP, Herrmann K, Strosberg J, Caplin M, Öberg K, Modlin IM. Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy. Lancet Oncol 2020;21:e431-43. [PMID: 32888472 DOI: 10.1016/S1470-2045(20)30323-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Camus B, Cottereau AS, Palmieri LJ, Dermine S, Tenenbaum F, Brezault C, Coriat R. Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review. J Clin Med 2021;10:1267. [PMID: 33803817 DOI: 10.3390/jcm10061267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Syguła A, Ledwon A, Hasse-Lazar K, Jurecka-Lubieniecka B, Michalik B, Paliczka-Cieślik E, Zeman M, Chmielik E, Sczasny J, Jarzab B, Handkiewicz-Junak D. In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2022. [PMID: 35503379 DOI: 10.1007/s00259-022-05792-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Merola E, Michielan A, Rozzanigo U, Erini M, Sferrazza S, Marcucci S, Sartori C, Trentin C, de Pretis G, Chierichetti F. Therapeutic strategies for gastroenteropancreatic neuroendocrine neoplasms: State-of-the-art and future perspectives. World J Gastrointest Surg 2022; 14(2): 78-106 [DOI: 10.4240/wjgs.v14.i2.78] [Reference Citation Analysis]
4 Te Beek ET, Burggraaf J, Teunissen JJM, Vriens D. Clinical Pharmacology of Radiotheranostics in Oncology. Clin Pharmacol Ther 2022. [PMID: 35373336 DOI: 10.1002/cpt.2598] [Reference Citation Analysis]
5 Sistani G, Sutherland DEK, Mujoomdar A, Wiseman DP, Khatami A, Tsvetkova E, Reid RH, Laidley DT. Efficacy of 177Lu-Dotatate Induction and Maintenance Therapy of Various Types of Neuroendocrine Tumors: A Phase II Registry Study. Curr Oncol 2020;28:115-27. [PMID: 33622997 DOI: 10.3390/curroncol28010015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Swiha MM, Sutherland DEK, Sistani G, Khatami A, Abazid RM, Mujoomdar A, Wiseman DP, Romsa JG, Reid RH, Laidley DT. Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS). J Cancer Res Clin Oncol 2021. [PMID: 34110489 DOI: 10.1007/s00432-021-03672-w] [Reference Citation Analysis]
7 Aerts A, Eberlein U, Holm S, Hustinx R, Konijnenberg M, Strigari L, van Leeuwen FWB, Glatting G, Lassmann M. EANM position paper on the role of radiobiology in nuclear medicine. Eur J Nucl Med Mol Imaging 2021. [PMID: 33912987 DOI: 10.1007/s00259-021-05345-9] [Reference Citation Analysis]
8 Bodei L, Herrmann K, Schöder H, Scott AM, Lewis JS. Radiotheranostics in oncology: current challenges and emerging opportunities. Nat Rev Clin Oncol 2022. [PMID: 35725926 DOI: 10.1038/s41571-022-00652-y] [Reference Citation Analysis]
9 Ahmadi Bidakhvidi N, Goffin K, Dekervel J, Baete K, Nackaerts K, Clement P, Van Cutsem E, Verslype C, Deroose CM. Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies. Cancers (Basel) 2021;14:129. [PMID: 35008293 DOI: 10.3390/cancers14010129] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Briest F, Koziolek EJ, Albrecht J, Schmidt F, Bernsen MR, Haeck J, Kühl AA, Sedding D, Hartung T, Exner S, Welzel M, Fischer C, Grötzinger C, Brenner W, Baum RP, Grabowski P. Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? - A preclinical assessment in vitro and in vivo. Neoplasia 2021;23:80-98. [PMID: 33246310 DOI: 10.1016/j.neo.2020.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 O'neill E, Cornelissen B. Know thy tumour: Biomarkers to improve treatment of molecular radionuclide therapy. Nuclear Medicine and Biology 2022. [DOI: 10.1016/j.nucmedbio.2022.02.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Roll W, Weckesser M, Seifert R, Bodei L, Rahbar K. Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management. Eur J Nucl Med Mol Imaging 2021. [PMID: 33903926 DOI: 10.1007/s00259-021-05359-3] [Reference Citation Analysis]
13 Rizzo A, Annunziata S, Salvatori M. Side effects of theragnostic agents currently employed in clinical practice. Q J Nucl Med Mol Imaging 2021;65:315-26. [PMID: 34881848 DOI: 10.23736/S1824-4785.21.03411-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Weber HC. Gastrointestinal regulatory peptides. Curr Opin Endocrinol Diabetes Obes 2022;29:167-8. [PMID: 35197424 DOI: 10.1097/MED.0000000000000719] [Reference Citation Analysis]
15 Bräutigam K, Rodriguez-Calero A, Kim-Fuchs C, Kollár A, Trepp R, Marinoni I, Perren A. Update on Histological Reporting Changes in Neuroendocrine Neoplasms. Curr Oncol Rep 2021;23:65. [PMID: 33855635 DOI: 10.1007/s11912-021-01062-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Siebinga H, de Wit-van der Veen BJ, Beijnen JH, Stokkel MPM, Dorlo TPC, Huitema ADR, Hendrikx JJMA. A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68Ga-DOTATATE in patients without neuroendocrine tumors. EJNMMI Res 2021;11:73. [PMID: 34398356 DOI: 10.1186/s13550-021-00821-7] [Reference Citation Analysis]